Actively Recruiting
Vaccine-induced Immunity in Immunocompromised Patients
Led by University of Cologne · Updated on 2026-05-12
1000
Participants Needed
1
Research Sites
248 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals. In hematological patients, poor humoral immunogenicity is common, especially when the B cell axis is affected by disease or treatment, while T cell responses may offer better protection. Current immunologic data on these patients is limited, focusing mostly on serologic parameters. To address this, we will conduct an observational study analyzing early and late booster vaccinations, with a focus on virus-specific T cell responses in vaccinated patients.
CONDITIONS
Official Title
Vaccine-induced Immunity in Immunocompromised Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form
- Patients with immunosuppression either by treatment or underlying diseases
- Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in accordance with current recommendations
- Age of 18 years or older
You will not qualify if you...
- Patients unwilling or ineligible for vaccination under current recommendations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Cologne
Cologne, North Rhine-Westphalia, Germany, 50937
Actively Recruiting
Research Team
S
Sibylle Mellinghoff, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here